NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
September 14, 2004 • Volume 1 / Number 35 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Article

NCI Launches Nanotechnology Alliance

Two panel discussions held yesterday at the National Institutes of Health (NIH) - one for science reporters and one for researchers - marked the launch of the National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer, a $144.3 million, 5-year initiative that brings together the physical, biological, and medical science communities for a common goal: directing nanotechnology for the benefit of cancer patients.

"Today we have the opportunity to renew our commitment to the conquest of cancer," said NCI Director Dr. Andrew C. von Eschenbach. "We're talking about an emerging field of great promise, and an old problem of great devastation that requires new hope."

Representatives from cancer centers, industry, and federal agencies attended the discussion in person and via teleconference and webcast. Dr. Anna Barker, deputy director of NCI's Advanced Technologies and Strategic Partnerships, gave a brief overview of its components: funding research through three to five Centers of Cancer Nanotechnology Excellence, as well as individual investigators; fostering multidisciplinary team assembly via interdisciplinary training; and establishing a Nanotechnology Characterization Laboratory at NCI's Frederick, Md., facility. Read more  

Director's Update

Realizing the Promise of Nanotechnology

Yesterday marked the official launch of the NCI Alliance for Nanotechnology in Cancer, an initiative that I believe could be a transformational event that moves the science of nanotechnology from a promising medical application to a central component in a new era in the diagnosis, monitoring, prevention, and treatment of cancer. When combined with the strides we have made in understanding cancer at the genetic, cellular, and molecular levels, nanotechnology may provide a whole new category of interventions that were not envisioned even 5 to 10 years ago.

The potential uses of nanodevices are staggering. Early research indicates, for instance, that nanosystems may allow for real-time assessments of therapeutic and surgical procedures, enabling clinicians to rapidly determine whether a treatment is working. Other work has shown the ability of targeted nanodevices to elude biological blockades and transport high concentrations of multiple therapeutics directly to cancer cells and the tissues in their immediate microenvironment. In this way, not only are healthy cells spared, but malignant cells and their allies in metastasis are eliminated. Nanotechnology also is making existing technologies more effective. In research presented at the American Association for Cancer Research annual meeting in March, for example, NCI researchers presented results from work in mice that showed that a nanoscale contrast agent vastly enhanced the ability of MRI to detect breast cancer lymph node metastases. Read more  


This NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads a national effort to eliminate the suffering and death due to cancer. Through basic and clinical biomedical research and training, NCI conducts and supports research that will lead to a future in which we can prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.